Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Mucopolysaccharidosis III-A
- Main trialPhase 1/2
- “A Phase I/ II, open-label, randomized, 2-arm study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.”In the company’s words, NCT06095388 on ClinicalTrials.gov
- Other names
- posnafusp alfa
Other drugs for Mucopolysaccharidosis III-A
Coming up1
- 31 Oct 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 31 Oct 2029 | Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026